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Abstract
Background: Antibodies to key Plasmodium falciparum surface antigens have been shown to be important
effectors that mediate clinical immunity to malaria. The cross-strain fraction of anti-malarial antibodies may
however be required to achieve
strain-transcending immunity. Such antibody responses against Plasmodium falciparum apical membrane antigen 1
(PfAMA1), a vaccine target molecule that is expressed in both liver and blood stages of the parasite, can be elicited
through immunization with a mixture of allelic variants of the parasite molecule. Cross-strain antibodies are most
likely elicited against epitopes that are shared by the allelic antigens in the vaccine cocktail.
Methods: A standard competition ELISA was used to address whether the antibody response can be further
focused on shared epitopes by exclusively boosting these common determinants through immunization of rabbits
with different PfAMA1 alleles in sequence. The in vitro parasite growth inhibition assay was used to further evaluate
the functional effects of the broadened antibody response that is characteristic of multi-allele vaccine strategies.
Results: A mixed antigen immunization protocol elicited humoral responses that were functionally similar to those
elicited by a sequential immunization protocol (p > 0.05). Sequential exposure to the different PfAMA1 allelic
variants induced immunological recall of responses to previous alleles and yielded functional cross-strain antibodies
that would be capable of optimal growth inhibition of variant parasites at high enough concentrations.
Conclusions: These findings may have implications for the current understanding of the natural acquisition of
clinical immunity to malaria as well as for rational vaccine design.
Background
Malaria caused by parasites of the Plasmodium spp. con-
tinues to be a major public health problem with half of
the world’s population at risk of infection [1]. The great-
est risk of disease and fatality in Plasmodium falci-
parum-endemic areas occurs in children under 5 years
and in first-time pregnant women. Natural immunity to
clinical malaria is believed to develop in an age- and
exposure-dependent manner, after repeated infection by
a number of (different) parasite strains [2-4]. Even in
adults who have had several parasite encounters,
acquired clinical immunity is partial and is believed to
be dependent on constant or periodic exposure to
low-level parasitaemia [3,5].
The natural ability to acquire immunity to malaria,
although partial, is a strong indication of the feasibility
of developing at least an anti-disease vaccine directed
against the blood stages of Plasmodium. Antigenic
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provides an immune escape route for parasites. Poly-
morphism in such well-known vaccine targets as the
Merozoite Surface Proteins (MSPs) and Apical Mem-
brane Antigen 1 (AMA1) have been associated with
host immune pressure on parasites [6-10]. This pre-
sents malaria vaccine researchers with a formidable
challenge since immunization with one variant of these
polymorphic antigens induces antibodies that show
limited cross-inhibition/recognition of parasites expres-
sing other allelic variants of the same antigen. This has
been demonstrated extensively in animal models
[11,12] and to some extent in human field studies
[13-16].
There is growing interest in multi-allele/multi-antigen
malaria vaccines and the potential of such vaccines for
the induction of broad inhibitory antibody responses has
been demonstrated [17-19]. The broadened response
most likely results from diluting out strain-specific epi-
topes in the antigen mixture, with the bulk of remaining
epitopes being those that are common to the vaccine
component alleles [20].
The hypothesis that immunization of rabbits with
different PfAMA1 alleles in sequence would result in
boosting of only antibodies to epitopes that are com-
mon to all antigens was tested in this study. Antibo-
dies to highly specific epitopes would not be boosted,
and this is expected to further increase the proportion
of induced cross-strain antibodies in comparison with
antibodies induced by a multi-allele vaccine that incor-
porates the same allelic antigens. Such a mechanism of
cross-strain antibody production would be based on
the concept of original antigenic sin (clonal imprint-
ing). Original antigenic sin results when prior exposure
to one strain/antigen diverts the antibody response to
shared epitopes following exposure to a second closely
related strain/antigen such that the newly elicited anti-
bodies still react strongly with the priming antigen
[21-23]. A sequential immunization protocol may
mimic the development of natural clinical immunity
and provide some insight into its acquisition in the
field where over time an individual is exposed (sequen-
tially) to a number of variant parasite strains. The gen-
erated data shows that a sequential immunization
protocol may not be materially different from a mixed
antigen protocol with respect to the proportions of eli-
cited strain-specific and cross-strain antibodies. As
expected, antibody producti o ni nt h es e q u e n t i a li m m u -
nization groups was through associative immune recall
of previous antigen encounter. This data is relevant to
the current understanding of the acquisition of clinical
immunity against malaria in endemic areas, as well as
for rational vaccine design.
Methods
Antigen production, rabbit immunization and antibody
purification
The full ectodomain of the AMA1 allelic forms from
P. falciparum strains FVO, HB3, 3D7 and CAMP, as
well as the in silico-designed Diversity Covering antigens
(DiCo 1, DiCo 2 and DiCo 3) [24], were expressed as
recombinant proteins in Pichia pastoris. The three DiCo
proteins were all expressed with the FVO AMA1 prodo-
main, and all antigens were mutagenized at up to six
potential N-glycosylation sites within the PfAMA1 ecto-
domain. The expression, purification and characterisa-
tion of all antigens were as described previously [25].
Rabbit housing and immunization were at BioGenes
GmbH (Berlin, Germany), and were in accordance with
national and international animal welfare regulations.
Rabbit immunization at this facility was under approval
from NIH/OLAW (ID number #A5755-01). Five groups
of rabbits were immunized intramuscularly with three
doses (30 μg per dose) of different PfAMA1 vaccine for-
mulations either in sequence or as an antigen cocktail
on days 0, 28 and 56. All vaccines were formulated in a
modified Freund’s adjuvant (95% paraffin oil, 2.4%
Tween 40, 0.1% cholesterol and 0.01% lipo-polysacchar-
ide from blue-green algae) provided by BioGenes, and
formulation was according to the manufacturer’sp r o t o -
cols. Three of the groups were immunized with
PfAMA1 alleles from the FVO, HB3 and 3D7 strains of
P. falciparum in different orders (details in Table 1). A
fourth group was immunized with three doses of an
equimolar mixture of these three alleles (designated as
NA mix, 10 μg of each allele, 30 μg dose), and the last
group was immunized with three doses of an equimolar
Table 1 Schedule indicating the order of PfAMA1 antigen
administration to rabbits
Immunization
group
Antigens and immunization *Number of
rabbits
Day 0 Day 28 Day 56
1 (f3h) FVO
AMA1
3D7
AMA1
HB3
AMA1
6
2 (hf3) HB3
AMA1
FVO
AMA1
3D7
AMA1
6
3 (h3f) HB3
AMA1
3D7
AMA1
FVO
AMA1
4
4 (NA mix) NA mix NA mix NA mix 6
5 (DiCo mix) DiCo
mix
DiCo
mix
DiCo
mix
6
f (FVO), 3 (3D7) and h (HB3) in groups 1, 2 and 3 indicate the order of antigen
administration.
NA mix - an equimolar mixture of AMA1 antigens from the FVO, HB3 and 3D7
strains of P. falciparum, administered at all three immunization time points.
DiCo mix - an equimolar mixture of the three Diversity-covering (DiCo)
proteins, administered at all three immunization time points.
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Page 2 of 11mixture of the three DiCo proteins (10 μg of each DiCo,
30 μg dose), referred to as DiCo mix (Table 1). Rabbits
were exsanguinated on day 70 and sera from all five
groups were analysed in ELISA while purified antibodies
from these sera were used in growth inhibition assays
described here.
Antibodies from final bleed sera were purified on
Protein G Sepharose (GE Healthcare, Etten-Leur, The
Netherlands) columns. Binding and elution buffers
(Pierce, Rockford, IL) were used according to manufac-
turer’s protocols. After elution, antibody eluates were fil-
tered (0.22 μm), concentrated and exchanged into RPMI
1640 using pre-sterilized Amicon Ultra-15 tubes
(30-kDa cutoff; Millipore, Ireland). The concentration of
each antibody fraction was subsequently determined by
a Nanodrop ND1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE) using the IgG extinction
coefficient, adjusted to 12 mg/ml and stored at -20°C
until use.
ELISA and growth inhibition assays
Sera from all rabbits were titrated in a standardized
ELISA on plates coated with recombinant AMA1 alle-
lic antigens from FVO, HB3 or 3D7 parasite strains.
Sera were also analysed with a harmonized competi-
tion ELISA protocol that has been described elsewhere
[20]. FVO, HB3 and 3D7 AMA1 proteins were used as
capture antigens and FVO, HB3, 3D7 and CAMP
AMA1 antigens were used as competitor antigens in
all assays.
Protein G-purified IgG fractions from final bleed sera
were tested for in vitro activity in parasite growth inhibi-
tion assays (GIAs). All IgGs were tested in triplicate on
FCR3 (one amino acid difference in the pro-domain
from the FVO strain, with ama1 GenBank accession no.
M34553), NF54 (parent strain of the 3D7 clone with
ama1 GenBank accession no. U65407), HB3 (accession
no. U33277), 7G8 (accession no. M34555) and CAMP
(accession no. M34552) parasite strains at a 2-fold serial
dilution from 6 mg/ml in 96-well half area cell culture
plates (Greiner, Alphen a/d Rijn, The Netherlands).
Parasites were cultured under standard conditions (an
atmosphere of 5% CO2,5 %O 2,a n d9 0 %N 2,3 7 ° C ) ,a n d
all parasite strains were verified by PCR and restriction
fragment length analysis of the PfAMA1 antigen they
express. Parasite cultures were mycoplasma-free and
synchronized with 0.3 M Alanine, 10 mM Hepes, pH
7.5 before use in assays. Late trophozoite/early schizont
stages at a parasitaemia of 0.3 ± 0.1% and 2% final hae-
matocrit were used in all assays. The final culture
volume was 50 μl/well and parasites were incubated for
42-46 h. Parasite growth was assessed by measuring
parasite lactate dehydrogenase levels and plates were
read at 655 nm after 30 min of development. Parasite
growth inhibition was expressed as 100 - ((A655Sample -
A655RBC)/(A655SZ - A655RBC)) × 100, where A655Sample
is the OD655 for any test sample well, A655SZ is the
average OD655 of schizont control wells included on
each plate and A655RBC is the average OD655 of RBC
control wells. The data is presented as the arithmetic
mean% inhibition from each sample triplicate.
Statistical analyses
All analyses and graphics were made using the R statisti-
cal package (R Development Core Team, 2009, version
2.10.1). ELISA antibody titres in day 70 sera were log-
transformed and compared between groups by one-way
analysis of variance (ANOVA) followed by the pair-wise
Tukey Honest Significant Difference post hoc test which
applies a correction for multiple comparisons. Titres are
also presented as dotplots superposed with boxplots
indicating the median, lower and upper quartiles.
Residual antibody binding (Ymin) for each competitor
antigen in competition ELISA was estimated by a
4-parameter logistic fit with least squares approxima-
tion. The mean % depletion (100-Ymin) and correspond-
ing 95% confidence intervals (95% CI) for each
competitor antigen are presented for all immunization
groups. GIA data is presented as the mean % growth
inhibition ± standard error of mean per immunization
group against the five parasite strains. Associations
between antibody titre and the corresponding in vitro
parasite growth inhibition levels were estimated with a
four-parameter logistic fit. Differences were considered
statistically significant at p < 0.05, or when the 95% CI
of groups being compared did not overlap.
One of the 6 rabbits in the first immunization group
(f3h) experienced pneumonia during the study and data
from this rabbit was excluded from all analyses. Rabbits
(n = 4) in one of the sequential groups (h3f, Table 1)
were immunized in a different experiment.
Results
Specificity of antibodies elicited with mixed allele and
sequential allele immunization protocols
Antibodies from rabbit sera drawn on day 70 from all
five groups were titrated against PfAMA1 alleles from
FVO, HB3 and 3D7 parasite strains, and the data is pre-
sented in Figure 1. There were no statistically significant
differences for comparisons of the log-transformed anti-
body titres either for any single immunization group
against all three capture antigens, or for the different
immunization groups against the same capture antigen
(P > 0.05, one-way ANOVA). Pair-wise comparison of
antibody titres for an immunization group against any
two capture antigens, or titres for any two groups
against the same capture antigen also showed no signifi-
cant differences (P > 0.05, Tukey HSD).
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Page 3 of 11Competition ELISA was performed to assess the
relative proportions of cross-reactive and strain-specific
antibodies induced against the individual vaccine anti-
gens and a fourth PfAMA1 allele (CAMP) that was not a
component of any of the vaccines. The FVO, HB3 and
3D7 AMA1 allelic proteins were used as capture antigens
a n dF V O ,H B 3 ,3 D 7a n dC A M PA M A 1a sc o m p e t i t o r
antigens. Depletion (%) of antibodies with the different
competitor antigens against each capture antigen is pre-
sented in Table 2. On each capture antigen, complete
depletion of antibodies by the homologous competitor
antigen was observed as expected. Heterologous antibody
depletion was however dependent on the number of
amino acid differences between the capture and competi-
tor antigens (presented in Figure 2). For example, deple-
tion was lowest for 3D7 AMA1 competitor antigen when
FVO AMA1 was used as capture antigen, and lowest for
CAMP AMA1 when HB3 AMA1 was used as capture
antigen (Table 2).
Comparison of the three sequential immunization
groups (f3h, hf3 and h3f) showed that though there
were small differences (based on overlaps in 95% CI,
Table 2) in the extent of heterologous antibody deple-
tion, no clear trends emerged with respect to the order
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Figure 1 Absolute levels of anti-AMA1 antibodies elicited with mixed allele and sequential allele protocols in rabbits. Rabbits in groups
1 - 3 were immunized with three PfAMA1 allelic antigens (from FVO, HB3 and 3D7 parasite strains) in three different sequences (refer to
Table 1). The fourth group of rabbits was immunized with a cocktail of the three PfAMA1 alleles, while the fifth group was immunized with a
mixture of the three Diversity covering proteins (DiCo mix) at all immunization time points. All vaccines were formulated with a modified
Freund’s adjuvant containing a lipo-polysaccharide from blue-green algae as adjuvant. Antibody titres of sera taken on day 70 were determined
by a standardized ELISA with 3D7 (left panel), FVO (middle panel) and HB3 (right panel) AMA1-coated plates. Data is presented on a Log2 scale
as dotplots with a boxplot superpose indicating the median, lower and upper quartiles per immunization group. For each capture antigen,
plotting symbols represent the antibody titre of individual rabbits within an immunization group.
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Page 4 of 11Table 2 Mean % antibody depletion from FVO, HB3 and 3D7 AMA1-coated plates
Coating antigen Competitor antigen Gp 1 (f3h) n = 5 Gp 2 (hf3) n = 6 Gp 3 (h3f) n = 4 Gp 4 (NA mix) n = 6 Gp5 (DiCo mix) n = 6
FVO AMA1 FVO 98.5 (97.3 - 99.7) 95.9 (95.1 - 96.8) 98.2 (96.3 - 100.1) 96.8 (95.4 - 98.2) 97.6 (96.4 - 98.7)
HB3 93.2 (88.1 - 98.3) 90.4 (87.0 - 93.8) 93.2 (86.0 - 100.4) 90.6 (87.4 - 93.9) 91.3 (89.7 - 92.9)
3D7 84.5 (77.5 - 91.5) 75.5 (74.3 - 76.7) 76.6 (65.4 - 87.8) 70.4 (64.7 - 76.0) 77.0 (69.4 - 84.7)
CAMP 78.7 (73.6 - 83.7) 70.3 (65.9 - 74.6) 74.2 (64.4 - 84.1) 70.3 (64.7 - 74.0) 84.0 (82.3 - 85.8)
HB3 AMA1 FVO 87.5 (79.0 - 96.0) 86.0 (81.2 - 90.9) 91.4 (89.3 - 93.6) 86.6 (83.3 - 89.9) 84.1 (80.6 - 87.5)
HB3 96.1 (93.6 - 98.5) 97.5 (95.4 - 99.6) 98.2 (98.1 - 98.4) 96.7 (95.0 - 98.4) 95.6 (93.7 - 97.4)
3D7 86.7 (82.3 - 91.0) 84.3 (75.9 - 92.8) 77.9 (70.5 - 85.4) 73.7 (66.7 - 80.6) 74.7 (70.5 - 78.9)
CAMP 76.8 (73.4 - 80.1) 68.5 (62.7 - 74.3) 74.4 (70.2 - 78.6) 66.8 (60.2 - 73.3) 81.2 (78.2 - 84.2)
3D7 AMA1 FVO 83.0 (75.3 - 90.8) 91.8 (86.7 - 97.0) 91.3 (84.8 - 97.9) 73.2 (66.1 - 80.3) 86.9 (84.4 - 89.4)
HB3 89.3 (85.2 - 93.4) 95.9 (92.7 - 99.1) 94.1 (89.2 - 99.0) 83.6 (76.1 - 91.1) 88.7 (86.2 - 91.2)
3D7 100.2 (96.8 - 103.7) 98.2 (95.9 - 100.2) 96.8 (94.6 - 99.0) 95.8 (94.3 - 97.4) 97.1 (95.2 - 99.0)
CAMP 79.5 (71.6 - 87.5) 82.0 (77.0 - 87.1) 85.7 (77.0 - 94.5) 71.0 (66.5 - 75.5) 89.2 (86.0 - 92.4)
Values reported as mean (95% CI) per immunization group for the same competitor antigen on each coating antigen.
*----30---*----40---*----50---*----60---*----70---*----80---*----90---*----100--*----110--*----120--*----130--*----140--*----150---
FCR3 QNYWEHPYQKSGVYHPINEHREHPKEYEYPLHQEHTYQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKG
HB3 ---------N-D--R---------------------------------------------------------------------------------K----------------------------------
NF54 ---------N-D--R--------------------------------------------------------------------------------------------------------------------
CAMP ---------N-N---------------Q-------------------------------------------------------------------------------------------------------
7G8 -----------D-----------S-----------------------------------------------------------------------K-----------------------------------
nDiCo 1 -----------D-----------------------------------------------------------------------------------------------------------------------
nDiCo 2 -----------D-----------------------------------------------------------------------------------------------------------------------
nDiCo 3 -----------D-----------------------------------------------------------------------------------------------------------------------
----160--*----170--*----180--*----190--*----200--*----210--*----220--*----230--*----240--*----250--*----260--*----270--*----280----
FCR3 IIIENSNTTFLKPVATGNQDLKDGGFAFPPTNPLISPMTLNGMRDFYKNNEYVKNLDELTLCSRHAGNMNPDNDKNSNYKYPAVYDYNDKKCHILYIAAQENNGPRYCNKDQSKRNSMFCFRPAKDKLFEN
HB3 ------K----T----E--------------E--------DQ--HL--D--------------------------------------E-----------------------E-------------------
NF54 -----------T-------Y-----------E--M-----DE--H---D-K------------------I----------------DK-----------------------E--------------IS-Q-
CAMP -------------------------------E----------------------------------------K-E-----------DK-----------------------E---------------S-Q-
7G8 ----------------------------------------DH---------------------------------------------------------------------E---------------S-Q-
nDiCo 1 ------Q----T----E--------------K--M-----DQ--H---D-K------------------I-----------------E-----------------------E---------------S-Q-
nDiCo 2 ------K----T----E--------------E------------------------------------------E------------------------------------E-------------------
nDiCo 3 ------Q---------------------------M-----DD---L--D-------------------------------------DK--------------------------------------IS-Q-
---290--*----300--*----310--*----320--*----330--*----340--*----350--*----360--*----370--*----380--*----390--*----400--*----410-----
FCR3 YTYLSKNVVDNWEEVCPRKNLENAKFGLWVDGNCEDIPHVNEFSANDLFECNKLVFELSASDQPKQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNRETQKCEIFNVKPT
HB3 ----------------------------------------------------------------------------------------------------------R----------T-------------
NF54 -------------K-------Q---------------------P-I-----------------------------------------------------------------------T-------------
CAMP -------------K--------------------------------------------------------------------------------------------------------K-H----------
7G8 -------------K--------------------------------------------------------------------------------------------R-----------K------------
nDiCo 1 -V-----------K-------------------------------I----------------------------------------D--R----------------------------K------------
nDiCo 2 -V-----------K------------------------------------------------------------------------D--R----------------------------K------------
nDiCo 3 -V-------H-----------Q----------------------------------------------------------------D--R----------------R----------T-------------
--420--*----430--*----440--*----450--*----460--*----470--*----480--*----490--*----500--*----510--*----520--*----530--*----540---
FCR3 CLINNSSYIATTALSHPIEVEHNFPCSLYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCPCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDNM
HB3 -----------------N---N--------------------------------------------------------I------N--------K---------------------------------
NF54 ---------------------N-----------M--------------------------------------------------------------------------------------------K-
CAMP ---------------------N--------N--M----------------------------------------------------------------------------------------------
7G8 -----------------N-------------------------------------------------I----------I------N--------K-------------------------------K-
nDiCo 1 ----DK------------------------------------------------------------------------I--Q---N--------K-------------------------------K-
nDiCo 2 ----DK------------------------N--M--------------------------------------------I--Q---N--------K-------------------------------K-
nDiCo 3 ----DK-----------N---N---------------------------------------------I-------A-----Q----------------------------------------------
Figure 2 Protein sequence (aa 25 - 545) alignments for DiCo antigens and parasite AMA1 alleles. The recombinant AMA1 allelic antigens
for FVO, HB3, 3D7 and CAMP used in ELISA differ at 6 positions (5 for HB3 AMA1) from the respective parasite sequences presented here. These
differences (N162Q, T288V, S373 D, N422 D, S423K, N499Q) were introduced in the recombinant antigens to prevent N-glycosylation of the Pichia
pastoris-expressed antigens.
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Page 5 of 11of antigen administration and the capture antigen used
in assays. The three sequential immunization groups
also showed detectable quantities of antibodies that
were specific to each of the three vaccine PfAMA1
alleles in all polyclonal pools on day 70, despite the fact
that each allelic antigen was administered at only one of
the three time points.
Comparisons across all groups showed that antibody
depletion by heterologous competitor antigens was gen-
erally lowest in the NA mix immunization group com-
pared to the three sequential immunization groups (f3h,
hf3 and h3f, Table 2). The observed differences were
however not always statistically significant since 95% CI
sometimes overlapped. Antibody depletion by CAMP
AMA1, an allele that was not in any of the vaccine for-
mulations, was greatest for antibodies from the DiCo
mix vaccine group compared to the other four groups
in all assays (Table 2). CAMP AMA1 depletion of anti-
DiCo mix antibodies was statistically significantly higher
than that of anti-NA mix antibodies irrespective of the
capture antigen, while differences between anti-DiCo
mix antibodies and the sequential immunization groups
were not always statistically significant (Table 2).
Functional capacity of antibodies elicited with mixed
allele and sequential allele immunization protocols
Protein G-purified antibodies from day 70 bleeds were
used for in vitro growth inhibition assays. Antibodies
from the three sequential immunization groups (f3h, hf3
and h3f) at 6 mg/ml showed similar mean levels of inhi-
bition of two of the three parasites expressing the vac-
cine alleles (FCR3, p = 0.60; HB3, p = 0.28; one-way
ANOVA) irrespective of the order of antigen adminis-
tration (Figure 3). Mean inhibition levels against the
NF54 strain were however higher for antibodies from
the f3h group compared to those from the h3f group (p
= 0.02, Tukey HSD). Pair-wise comparisons of mean
growth inhibition levels in any sequential immunization
group with that of the NA mix group against any of the
parasites showed no significant differences (p > 0.05,
Tukey HSD) despite the weak trend of high antibody
depletions from the sequential immunization groups in
competition assays (Table 2). Thus it did not matter
whether the vaccine was administered as a mixture or in
sequence, the functional outcome in vitro was the same.
Antibodies from the sequential (f3h, hf3 and h3f) and
NA mix immunization groups generally showed a
r e d u c t i o ni nt h ee x t e n to fin vitro inhibition of “het-
erologous” parasite strains (CAMP, 7G8) compared to
that of “homologous” strains (NF54, FCR3, HB3).
Mean inhibition with antibodies from both the f3h (Gp
1 )a n dN Am i x( G p4 )i m m u n i z a t i o n sa t6m g / m lw e r e
all higher against “homologous” strains (NF54, HB3,
F C R 3 )c o m p a r e dt ot h o s ea g a i n s tt h eC A M Pa n d7 G 8
strains (p < 0.0001, one-way ANOVA). Mean inhibi-
tion of antibodies from the hf3 group (Gp 2) were
however only higher against HB3 strains when com-
pared pair-wise with the “heterologous” strains (p =
0.006 for 7G8 and p = 0.005 for CAMP parasites,
Tukey HSD). Antibodies from the h3f group (Gp 3)
also showed higher mean inhibition against HB3 in
comparison with the CAMP strain (p = 0.024, Tukey
HSD). In contrast, antibodies from the DiCo mix
group (Gp 5) showed a generally consistent level of
inhibition of all five parasite strains (Figure 3). Mean
growth inhibitions ranged from 47.2% against the
CAMP strain to 66.9% against the HB3 strain at 6 mg/
ml total IgG, and these were not statistically signifi-
cantly different (p = 0.55, one-way ANOVA).
The data generally suggests that effectiveness of the
antibody response was dependent on the test parasite
strain ("homologous” vs. “heterologous”), and the abso-
lute levels of elicited antibodies. Higher antibody titres
are expected to give greater in vitro parasite growth
inhibition levels since antibody titres against specific
alleles correlate well with the level of in vitro inhibition
of parasites expressing those alleles (Figure 4).
Discussion
An effective malaria vaccine is expected to confer simi-
lar or better immunity to malaria-susceptible individuals
compared to that of adults who are resident in endemic
areas, but over a shorter period of time. In semi-
immune adults, this level of anti-disease immunity is
acquired after repeated infection with diverse parasite
strains [2,3]. Antibodies are key components of anti-dis-
ease immunity [26,27], and the cross-strain fraction of
anti-malarial antibodies may be important effectors
against parasite strains that express diverse polymorphic
antigens [7,14,28]. The main objectives of this study
were to compare sequential and mixed PfAMA1 immu-
nization protocols for the proportions of functional
cross-strain antibodies they induce in rabbits, and to
further demonstrate the specificity broadening effects of
such vaccination strategies.
Statistically similar levels of antibodies were induced
with all vaccine formulations, irrespective of the order
of antigen administration (Figure 1). This suggests that
the order of antigen exposure may not influence the
levels of elicited antibodies. For sequential immunization
groups, this shows that “booster” responses were asso-
ciative recall responses of previous allele vaccinations,
and antibodies were mostly to epitopes that are shared
by vaccine alleles. This is consistent with published data
on both cellular and humoral immune responses to
other polymorphic malaria antigens [7,29-31], and is a
well-established phenomenon in immune responses to
other parasitic and viral infections [21,22,32-34].
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Page 6 of 11Antibody depletion data from competition assays
showed marginally higher proportions of cross-strain
antibodies in some sequential immunization groups
compared to the NA mix group (Table 2). Since signifi-
cance was achieved only in some instances and there
were no observable trends with respect to capture and
competitor antigens, the order of antigen administration
may only marginally influence the ultimate specificity of
antibodies on day 70. The three-antigen DiCo mix vac-
cine generally yielded higher proportions of cross-strain
antibodies compared to the three-antigen NA mix vac-
cine, especially against the out-group competitor antigen
CAMP (Table 2). This suggests that the three DiCo
antigens together present a greater proportion of
epitopes that induce broad-reacting antibodies, and
affirms the specificity broadening properties of the DiCo
vaccine approach [9,35].
The determination of strain-specific antibodies against
vaccine alleles in sequential immunization groups on
day 70 (Table 2) suggests that immunization with a sin-
gle allele does induce long-lived responses. This may
reflect the persistence of strain-specific antibodies that
were induced after antigen administration on day 0 (first
antigen), 28 (second antigen) or 56 (third antigen).
Alternatively, memory B cells to these specific antibody
epitopes in previous vaccine alleles could be activated by
the altered, corresponding low affinity epitopes on sub-
sequently administered PfAMA1 alleles, leading to high
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Figure 3 Growth inhibition of P. falciparum parasites by antibodies elicited with mixed and sequential allele protocols.P r o t e i n
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topes. The latter phenomenon is in agreement with the
mechanism underlying original antigenic sin, and sup-
ports the existence of a continuum of antibody specifici-
ties [7]. It must be noted that the specificity of an
antibody for an antigen is directly related to the affinity
of the antigen-antibody interaction hence an antibody
that is “specific” to one PfAMA1 allele may indeed have
very low affinity for other alleles.
Data from in vitro growth inhibition assays was con-
sistent with the observations in ELISA. The similar inhi-
bition of FCR3, HB3 and NF54 parasite strains by
purified antibodies from sequential immunization (f3h,
hf3 and h3f) and NA mix groups suggests that
comparable levels of functional antibodies against all
three parasite strains were present on day 70, irrespec-
tive of the order of antigen administration (Figure 3).
This confirms the induction of antibodies mostly to
shared epitopes based on the original antigenic sin phe-
nomenon [7,22].
The observed higher inhibition of parasite strains
expressing the vaccine alleles compared to the out-
group strains (CAMP, 7G8) may be attributed to the
generally low levels of antibodies induced in all immuni-
zation groups. A similar observation was made in an
earlier study where low titres of antibodies elicited
against DiCo mix in Montanide IMS resulted in lower
in vitro parasite inhibition levels compared with the
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Figure 4 ELISA antibody titre correlates with in vitro parasite growth inhibition. Association of antibody levels with in vitro antibody
functionality is shown for parasite strains FCR3 (FVO), HB3 and NF54 (3D7). In vitro inhibition of any parasite strain at 6 mg/ml of purified
antibody has been plotted against antibody titres measured with the corresponding AMA1 allele. Plots are based on a four-parameter logistic
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Page 8 of 11higher antibody levels against DiCo mix in two other
adjuvants [35]. ELISA antibody titres and parasite inhi-
bition levels in the present study are intermediate
between those of anti-DiCo mix antibodies elicited in
the previous study with Montanide IMS on the one
hand and CoVaccine HT™/Montanide ISA 51 on the
other hand. Similar proportions of cross-strain antibo-
dies were measured in both studies despite the different
absolute antibody titres. At such low antibody titres,
high avidity strain-specific antibodies, which form a
small proportion of elicited antibodies, most likely aug-
ment the functional effects of cross-strain antibodies
against the respective homologous parasite strains. This
fraction of strain-specific antibodies would however
have very low avidities for AMA1 of the CAMP and
7G8 strains, resulting in lower levels of inhibition of
these strains (Figure 3). Thus high titres of functional
cross-strain antibodies are required to optimally inhibit
“heterologous” strains. At high antibody titres, the addi-
tional inhibitory activity of any strain-specific antibodies
against “homologous” parasites would put the overall
inhibitory effect in the upper plateau region of the anti-
body binding-function curve (Figure 4). A possible lim-
itation here however, is that some parasites, here the
HB3 strain, may be inherently easier to inhibit than
others, and this could mask the effect of vaccine
responses described. Similar effect has been described
for D10 parasites, which can be inhibited better with
anti-3D7 AMA1 antibodies compared to inhibition of
the homologous 3D7 strain [36,37].
Although anti-DiCo mix antibodies least inhibited the
three “homologous” strains, these antibodies performed
as well against the two out-group parasite strains as
antibodies from all other vaccine formulations. Addi-
tionally, unlike the other vaccine formulations, anti-
DiCo mix antibodies showed consistent inhibition of all
parasite strains. This consistency, coupled with the sig-
nificantly higher depletion of anti-DiCo antibodies by
the out-group CAMP AMA1 competitor antigen when
compared to anti-NA mix antibodies, suggests that
DiCo mix may have a slight advantage as a vaccine can-
didate, since AMA1 from culture-adapted strains may
not necessarily be encountered in the field.
The current in vitro growth inhibition data may seem
inconsistent with our earlier published data [20], where
rabbit antibodies elicited with a three-antigen (FVO,
HB3, 3D7 AMA1) vaccine in Montanide ISA720 inhib-
ited a heterologous parasite strain (CAMP) to a similar
extent as the three “homologous” strains. This can how-
ever be explained by the fact that data from the earlier
study was based on a single sample per immunization
group, with antibody titres that were 2-4 times higher
than the average antibody titres in the study under dis-
cussion. The greater potency of the adjuvant used in the
earlier study may partially account for the higher titres.
Additionally, the earlier study used an immunization
protocol (4 vaccine doses on days 0, 28, 56 and 82,
exsanguination on day 95) that is different from the one
used in the current study (3 doses on days 0, 28 and 56,
exsanguination on day 70). The extra booster dose, as
well as the longer study period, could account partially
for the higher functional antibody titres, which were
most likely at saturation levels. It must be noted that
single allele immunizations with FVO, HB3 and 3D7
AMA1 alleles in the previous study also resulted in
similar antibody titres to that of the three-antigen mixed
allele vaccine but failed to achieve the same level of in
vitro inhibition of heterologous parasites as the mixed
allele vaccine [20]. Moreover, mixed allele vaccine anti-
bodies from both studies showed similar binding specifi-
cities for the component antigens. Thus high titres of
cross-strain antibodies are necessary for significant inhi-
bition of variant parasites, and this is consistent with
earlier published literature in both in vitro and in vivo
settings [28,35].
This data may aid current understanding of the acqui-
sition of clinical immunity to malaria in endemic areas.
Induction of antibodies to polymorphic antigens in the
field upon infection with different parasite strains may
be through an original antigenic sin mechanism, and
individuals will most likely accumulate a strain-trans-
cending repertoire of antibodies over time. This will also
explain why clinical testing of a mono-allelic vaccine
based on a polymorphic antigen in an unexposed popu-
lation yields antibodies that react better with homolo-
gous than heterologous antigenic alleles [13] while
antibodies taken after a similar trial in a malaria-ende-
mic population react equally well with both homologous
and heterologous vaccine alleles [38]. A mixture of
strain-specific and cross-strain antibodies are most likely
induced in naïve individuals in the former instance
while previous exposure in the latter results in a boost
of responses to epitopes that are common to the vaccine
and previously encountered alleles.
In summary, a mixed antigen immunization protocol
is expected to elicit humoral responses similar to those
elicited by a sequential immunization protocol, and by
extension the response induced naturally in individuals
in malaria-endemic populations. Thus the anti-AMA1
component of a natural immune response can be effec-
tively mimicked by immunization with a cocktail of
AMA1 alleles. This finding may also apply to the many
other polymorphic parasite antigens that are currently
undergoing clinical evaluation. Additionally, sequential
exposure to different AMA1 alleles induces immunolo-
gical recall of responses to previous alleles and yields
functional cross-strain antibodies that are capable of
optimal parasite growth inhibitions at high enough
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Page 9 of 11concentrations. These findings may aid current under-
standing of the natural acquisition of clinical immunity
to malaria as well as provide fresh insight into rational
vaccine design.
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